Zoetis Inc. (NYSE:ZTS) to Issue $0.53 Quarterly Dividend

Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Wednesday, May 20th. Stockholders of record on Monday, July 20th will be given a dividend of 0.53 per share on Tuesday, September 1st. This represents a c) dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th.

Zoetis has raised its dividend payment by an average of 0.2%annually over the last three years and has increased its dividend annually for the last 14 consecutive years. Zoetis has a dividend payout ratio of 31.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Zoetis to earn $7.42 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 28.6%.

Zoetis Stock Up 0.9%

ZTS stock opened at $79.64 on Thursday. Zoetis has a twelve month low of $72.38 and a twelve month high of $172.23. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The stock’s 50 day moving average is $109.69 and its 200-day moving average is $119.37. The firm has a market capitalization of $33.39 billion, a PE ratio of 13.21, a P/E/G ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the business earned $1.48 EPS. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts expect that Zoetis will post 6.88 EPS for the current fiscal year.

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by company insiders.

Institutional Trading of Zoetis

Hedge funds have recently bought and sold shares of the business. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the fourth quarter valued at $25,000. Prosperity Bancshares Inc bought a new stake in shares of Zoetis in the fourth quarter valued at $25,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis in the first quarter valued at $28,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the fourth quarter valued at $30,000. Finally, Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the period. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.